Investments
The Problem
Spine care intervenes too late. Traditional open surgery — and most minimally invasive spine surgery (MISS) — treats advanced degeneration with reconstructive fusion. These rigid procedures are associated with adjacent segment disease, rising revision rates, prolonged recovery, and escalating system costs.
Late diagnosis. Fusion dependence. A growing revision epidemic.
The Market
More than 500,000 lumbar fusion procedures are performed each year in the United States, reflecting a spine market still dominated by late-stage reconstructive surgery.
​
Our strategy is to move spine care upstream — away from fusion and toward earlier intervention with motion-preserving, anatomy-respecting technologies performed in the ambulatory surgery center (ASC) setting.
By treating patients earlier:
-
More patients become procedural candidates
-
Fear of spine surgery decreases
-
Cost barriers decline
If successful, we believe this shift could expand the spine total addressable market (TAM) by more than 3×.
​
We are building the patented technologies, standardized training, and ASC-optimized procedural model to lead that transformation.
The Solution
We are investing in motion-preserving spine technologies that move beyond traditional articulating ball-and-socket disc replacements toward viscoelastic designs that replicate the shock absorption and multi-directional motion of the natural human disc.
​
Our strategy is guided by the REP™ principles:
Restore Function| Early Diagnosis and Treatment | Preserve Anatomy and Motion
​
Together, these principles shift spine care away from late-stage reconstructive fusion and toward earlier, motion-preserving solutions enabled by LESS® Exposure Spine Surgery.
​
To scale these technologies globally, we focus on:
• Patented motion-preserving technologies
• Standardized surgeon training and certification
• Peer-reviewed clinical validation
• ASC-optimized procedural workflows
Our goal is to make spine surgery safer, more reproducible, and globally accessible, enabling patients to recover faster and return to active lives.
Series C Open
More than $95 million has been invested in AxioMed to date to advance the development of its motion-preserving disc replacement technologies. AxioMed is preparing to apply for FDA approval of its anterior lumbar disc in 2026, alongside plans to begin international commercialization.
​
The company is currently raising a Series C financing round, offering investors the opportunity to participate through self-directed IRAs (SDIRAs), enabling potential tax-advantaged or tax-free returns depending on account structure.
Institutional Investors Since 2001
